Prescription patterns of P2Y12 inhibitors following revascularization in the United States: 2013–2018

P2Y12 inhibitors (i.e., clopidogrel, prasugrel, or ticagrelor) are effective at reducing adverse cardiovascular outcomes post‐revascularization in coronary artery disease (CAD). However, the choice of a specific P2Y12 inhibitor may vary according to the patient's characteristics, and trends in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Arun, Lutsey, Pamela L., St. Peter, Wendy L., Schommer, Jon C., Van’t Hof, Jeremy R., Rajpurohit, Abhijeet, Farley, Joel F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582679/
https://www.ncbi.nlm.nih.gov/pubmed/37466284
http://dx.doi.org/10.1111/cts.13596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582679/
https://www.ncbi.nlm.nih.gov/pubmed/37466284
http://dx.doi.org/10.1111/cts.13596

Ejemplares similares